top of page

Focused-spectrum psychedelics for mental health

Fully integrated, pre-clinical stage biotechnology company developing therapeutics for accessible treatment of psychiatric diseases

Mission

Develop better and accessible treatments for psychiatric disorders derived from under-researched entheogenic compounds

Focus

Bring our lead compound, a psilocybin-synergistic tryptamine combination, that has shown pre-clinical evidence of better and longer-lasting efficacy, into clinical proof of concept in obsessive- compulsive disorder

Science

Leverage the neuroplastic effects of entheogen-derived molecules for psychiatric therapies

Dosing schedules and formulations that avoid the hallucinogenic effects

Microbial biomanufacturing platform

Achievements from discovery to the clinic

DISCOVERY

Major research correlating mushrooms, tryptamines and psychedelic experience

 

World-first, cell-based 5- MeO-DMT

PRE-CLINICAL

Demonstrated superiority of P601 over synthetic psilocybin including duration and efficacy in disease models and increased synaptic plasticity (biomarkers, IEG, behavioral phenotyping and metabolomics)

IP

Strong patent position for key indications and broad, defensible bio- manufacturing IP

​

8 filed patents

SCREENING

AI-based phenotypic screening in 2 non-human models

​

In-house fully equipped zebrafish laboratory for high throughput screening

​

LC-MS/MS, UHPLC-MS, MS- Flash, cell culture laboratory

MANUFACTURING

cGMP level biomass production facility

​

Proprietary extraction, purification and fractionation technology

 

Microbial manufacturing using novel method and technology

CLINICAL

OCD trial preparation with top-tier advisors

​

Health economics/RWE capabilities for future reimbursement strategies

bottom of page